European radiopharmaceutical company Artbio Therapeutics secured $132 million in Series B funding to advance its prostate cancer radioligand program into phase 2 clinical trials and expand its manufacturing capabilities. Led by former Novartis executive Emanuele Ostuni, Artbio focuses on developing targeted therapies competing with existing prostate cancer medicines, supported by a strengthened supply chain to scale clinical development.